PF-Atlas › Clinical Trials › NCT05154240
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
INS018_055 · Phase 1
Registry ID
NCT05154240
Phase
Phase 1
Status
Completed
Drug / intervention
INS018_055
Sponsor
InSilico Medicine Hong Kong Limited
Start
2022-02-21
Enrollment
78
Locations
1
About this trial
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018\_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose \[SAD\]) and Part B (multiple ascending dose \[MAD\]).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05154240 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.